SCHEMBL3600239

SCHEMBL3600239

CC(C)=CCC/C(C)=C/CNc1cccc(C(=O)O)c1

nearest known ligand 0.62

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TRPV1 Q8NER1 6/20 0.53
AKR1C3 P42330 1/20 0.48
POLB P06746 2/20 0.44
MAPT P10636 2/20 0.44
ICMT O60725 1/20 0.43
GMNN O75496 1/20 0.43
TRPA1 O75762 1/20 0.43
LMNA P02545 1/20 0.43
CYP1A2 P05177 1/20 0.43
CYP3A4 P08684 1/20 0.43
CYP2C9 P11712 1/20 0.43
TSHR P16473 1/20 0.43
NFKB1 P19838 1/20 0.43
CDK2 P24941 1/20 0.43
RECQL P46063 1/20 0.43
BLM P54132 1/20 0.43
HIF1A Q16665 1/20 0.43
HSD17B10 Q99714 1/20 0.43
MEN1 O00255 1/20 0.42
KMT2A Q03164 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3600241 1.00 TRPV1 (0.53) TRPV1AKR1C3POLBMAPTICMT
SCHEMBL8224018 0.99 TRPV1 (0.52) TRPV1AKR1C3POLBMAPTICMT
SCHEMBL3601215 0.90 AKR1C3 (0.46) TRPV1AKR1C3MEN1KMT2A
SCHEMBL1672629 0.88 AKR1C3 (0.56) AKR1C3POLBMAPTHIF1AMEN1
SCHEMBL3598188 0.88 TRPV1 (0.51) TRPV1POLBMAPTHIF1AHSD17B10
SCHEMBL3793148 0.88 TRPV1 (0.51) TRPV1POLBMAPTHIF1AHSD17B10
SCHEMBL8222368 0.86 TRPV1 (0.50) TRPV1POLBMAPTHSD17B10
SCHEMBL3598973 0.84 SMN1; SMN2 (0.50) TRPV1POLBMAPTLMNACYP1A2
SCHEMBL6654122 0.84 TRPV1 (0.51) TRPV1POLBMAPTICMTGMNN
SCHEMBL9058968 0.84 TRPV1 (0.51) TRPV1POLBMAPTICMTGMNN

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100041665-A1 N-PHENYL-PRENYLAMINE DERIVATIVES FOR THE TREATMENT OF COGNITIVE, NEURODEGENERATIVE OR NEURONAL DISEASES OR DISORDERS NOSCIRA, S.A. (ES) 2010-02-18 US disclosed
US-20100041665-A1 N-PHENYL-PRENYLAMINE DERIVATIVES FOR THE TREATMENT OF COGNITIVE, NEURODEGENERATIVE OR NEURONAL DISEASES OR DISORDERS NOSCIRA, S.A. (ES) 2010-02-18 US disclosed
US-20100041665-A1 N-PHENYL-PRENYLAMINE DERIVATIVES FOR THE TREATMENT OF COGNITIVE, NEURODEGENERATIVE OR NEURONAL DISEASES OR DISORDERS NOSCIRA, S.A. (ES) 2010-02-18 US disclosed
EP-2057114-A1 N-PHENYL-PRENYLAMINE DERIVATIVES FOR THE TREATMENT OF COGNITIVE, NEURODEGENERATIVE OR NEURONAL DISEASES OR DISORDERS NOSCIRA, S.A. (ES) 2009-05-13 EP disclosed
WO-2008015240-A1 N-PHENYL-PRENYLAMINE DERIVATIVES FOR THE TREATMENT OF COGNITIVE, NEURODEGENERATIVE OR NEURONAL DISEASES OR DISORDERS NOSCIRA, S.A. (ES) 2008-02-07 WO disclosed
WO-2008015240-A1 N-PHENYL-PRENYLAMINE DERIVATIVES FOR THE TREATMENT OF COGNITIVE, NEURODEGENERATIVE OR NEURONAL DISEASES OR DISORDERS NOSCIRA, S.A. (ES) 2008-02-07 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100041665-A1 N-PHENYL-PRENYLAMINE DERIVATIVES FOR THE TREATMENT OF COGNITIVE, NEURODEGENERATIVE OR NEURONAL DISEASES OR DISORDERS PNMT, PSEN1, SNCA TRPV1 1245/4885AKR1C3 1266/4885POLB 4139/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.